Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States
Abstract Background To compare quality of life of patients treated with cetuximab with or without radiation therapy (±RT) vs. cisplatin±RT for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) in the real-world setting. Methods In this retrospective observational study, el...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-06-01
|
Series: | Health and Quality of Life Outcomes |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12955-020-01424-x |
id |
doaj-4bbdccb926eb4645b3e424e7271cf9c2 |
---|---|
record_format |
Article |
spelling |
doaj-4bbdccb926eb4645b3e424e7271cf9c22020-11-25T03:29:44ZengBMCHealth and Quality of Life Outcomes1477-75252020-06-0118111410.1186/s12955-020-01424-xQuality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United StatesHimani Aggarwal0Rajeshwari S. Punekar1Li Li2Gebra Cuyun Carter3Mark S. Walker4Global Patient Outcomes and Real World Evidence, Eli Lilly and CompanyVector OncologyStatistics, R&G PharmaStudies Co., Ltd.Global Patient Outcomes and Real World Evidence, Eli Lilly and CompanyVector OncologyAbstract Background To compare quality of life of patients treated with cetuximab with or without radiation therapy (±RT) vs. cisplatin±RT for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) in the real-world setting. Methods In this retrospective observational study, electronic medical records and Patient Care Monitor (PCM) survey data from the Vector Oncology Data Warehouse were utilized from adult patients in the United States who received initial treatment with cetuximab±RT or cisplatin±RT for locoregionally advanced SCCHN between January 1, 2007 and January 1, 2017. Quality of life was assessed using PCM index scores and individual PCM items. Cetuximab±RT and cisplatin±RT cohorts were balanced using propensity score weighting. Linear mixed models were used to assess the impact of baseline demographic and clinical characteristics on PCM endpoints. Results Of 531 patients with locoregionally advanced SCCHN, 187 received cetuximab±RT, and 344 received cisplatin±RT. Before propensity score weighting, the cetuximab±RT cohort was older (mean [SD] age of 63.9 [9.6] years vs. 57.4 [8.6] years), and more likely to be white (82.4% vs. 72.4%) compared to the cisplatin±RT cohort. After propensity score weighting, the two cohort subsamples (cetuximab±RT, N = 60; cisplatin±RT, N = 177) with PCM data showed no significant differences in General Physical Symptoms, Treatment Side Effects, Impaired Ambulation, or Impaired Performance index scores. Patients in the cetuximab±RT cohort had higher Acute Distress index (p = 0.023), Despair index (p = 0.011), and rash (p = 0.003) scores but lower numbness/tingling scores (p = 0.022) than patients in the cisplatin±RT cohort. Conclusions Significant group differences were observed in this comparative analysis, as the cetuximab±RT cohort had significantly higher Acute Distress index, Despair index, and rash scores compared with the cisplatin±RT cohort but lower numbness/tingling scores. These patterns of symptoms appear consistent with previously reported symptoms associated with the treatment of SCCHN.http://link.springer.com/article/10.1186/s12955-020-01424-xQuality of lifeAdvanced squamous cell carcinoma of the head and neckCetuximabCisplatinRadiation therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Himani Aggarwal Rajeshwari S. Punekar Li Li Gebra Cuyun Carter Mark S. Walker |
spellingShingle |
Himani Aggarwal Rajeshwari S. Punekar Li Li Gebra Cuyun Carter Mark S. Walker Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States Health and Quality of Life Outcomes Quality of life Advanced squamous cell carcinoma of the head and neck Cetuximab Cisplatin Radiation therapy |
author_facet |
Himani Aggarwal Rajeshwari S. Punekar Li Li Gebra Cuyun Carter Mark S. Walker |
author_sort |
Himani Aggarwal |
title |
Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States |
title_short |
Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States |
title_full |
Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States |
title_fullStr |
Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States |
title_full_unstemmed |
Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States |
title_sort |
quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the united states |
publisher |
BMC |
series |
Health and Quality of Life Outcomes |
issn |
1477-7525 |
publishDate |
2020-06-01 |
description |
Abstract Background To compare quality of life of patients treated with cetuximab with or without radiation therapy (±RT) vs. cisplatin±RT for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) in the real-world setting. Methods In this retrospective observational study, electronic medical records and Patient Care Monitor (PCM) survey data from the Vector Oncology Data Warehouse were utilized from adult patients in the United States who received initial treatment with cetuximab±RT or cisplatin±RT for locoregionally advanced SCCHN between January 1, 2007 and January 1, 2017. Quality of life was assessed using PCM index scores and individual PCM items. Cetuximab±RT and cisplatin±RT cohorts were balanced using propensity score weighting. Linear mixed models were used to assess the impact of baseline demographic and clinical characteristics on PCM endpoints. Results Of 531 patients with locoregionally advanced SCCHN, 187 received cetuximab±RT, and 344 received cisplatin±RT. Before propensity score weighting, the cetuximab±RT cohort was older (mean [SD] age of 63.9 [9.6] years vs. 57.4 [8.6] years), and more likely to be white (82.4% vs. 72.4%) compared to the cisplatin±RT cohort. After propensity score weighting, the two cohort subsamples (cetuximab±RT, N = 60; cisplatin±RT, N = 177) with PCM data showed no significant differences in General Physical Symptoms, Treatment Side Effects, Impaired Ambulation, or Impaired Performance index scores. Patients in the cetuximab±RT cohort had higher Acute Distress index (p = 0.023), Despair index (p = 0.011), and rash (p = 0.003) scores but lower numbness/tingling scores (p = 0.022) than patients in the cisplatin±RT cohort. Conclusions Significant group differences were observed in this comparative analysis, as the cetuximab±RT cohort had significantly higher Acute Distress index, Despair index, and rash scores compared with the cisplatin±RT cohort but lower numbness/tingling scores. These patterns of symptoms appear consistent with previously reported symptoms associated with the treatment of SCCHN. |
topic |
Quality of life Advanced squamous cell carcinoma of the head and neck Cetuximab Cisplatin Radiation therapy |
url |
http://link.springer.com/article/10.1186/s12955-020-01424-x |
work_keys_str_mv |
AT himaniaggarwal qualityoflifeanalysisofpatientstreatedwithcetuximaborcisplatinforlocoregionallyadvancedsquamouscellcarcinomaofheadandneckintheunitedstates AT rajeshwarispunekar qualityoflifeanalysisofpatientstreatedwithcetuximaborcisplatinforlocoregionallyadvancedsquamouscellcarcinomaofheadandneckintheunitedstates AT lili qualityoflifeanalysisofpatientstreatedwithcetuximaborcisplatinforlocoregionallyadvancedsquamouscellcarcinomaofheadandneckintheunitedstates AT gebracuyuncarter qualityoflifeanalysisofpatientstreatedwithcetuximaborcisplatinforlocoregionallyadvancedsquamouscellcarcinomaofheadandneckintheunitedstates AT markswalker qualityoflifeanalysisofpatientstreatedwithcetuximaborcisplatinforlocoregionallyadvancedsquamouscellcarcinomaofheadandneckintheunitedstates |
_version_ |
1724577257482092544 |